ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
Overall ORGO gets a fundamental rating of 5 out of 10. We evaluated ORGO against 565 industry peers in the Biotechnology industry. ORGO scores excellent on profitability, but there are some minor concerns on its financial health. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
In the past year ORGO had a positive cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -1.65%, ORGO belongs to the best of the industry, outperforming 91.64% of the companies in the same industry.
ORGO has a better Return On Equity (-2.65%) than 92.70% of its industry peers.
ORGO has a Return On Invested Capital of 1.68%. This is amongst the best in the industry. ORGO outperforms 93.59% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 13.59%.
The 3 year average ROIC (6.08%) for ORGO is well above the current ROIC(1.68%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.65% | ||
| ROE | -2.65% | ||
| ROIC | 1.68% |
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of ORGO has declined.
With an excellent Operating Margin value of 2.20%, ORGO belongs to the best of the industry, outperforming 93.77% of the companies in the same industry.
ORGO's Operating Margin has declined in the last couple of years.
ORGO's Gross Margin of 75.29% is amongst the best of the industry. ORGO outperforms 85.05% of its industry peers.
ORGO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.2% | ||
| PM (TTM) | N/A | ||
| GM | 75.29% |
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ORGO is destroying value.
ORGO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.82 indicates that ORGO is not a great score, but indicates only limited risk for bankruptcy at the moment.
ORGO has a better Altman-Z score (2.82) than 74.38% of its industry peers.
ORGO has a debt to FCF ratio of 16.51. This is a negative value and a sign of low solvency as ORGO would need 16.51 years to pay back of all of its debts.
The Debt to FCF ratio of ORGO (16.51) is better than 92.70% of its industry peers.
ORGO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
ORGO has a worse Debt to Equity ratio (0.21) than 69.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 16.51 | ||
| Altman-Z | 2.82 |
ROIC/WACC0.16
WACC10.6%
2.3 Liquidity
A Current Ratio of 3.09 indicates that ORGO has no problem at all paying its short term obligations.
With a Current ratio value of 3.09, ORGO is not doing good in the industry: 63.52% of the companies in the same industry are doing better.
ORGO has a Quick Ratio of 2.74. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO's Quick ratio of 2.74 is on the low side compared to the rest of the industry. ORGO is outperformed by 66.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 2.74 |
3. Growth
3.1 Past
ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.00%, which is quite good.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -30.66% on average per year.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 1.37%.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.50% yearly.
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5YN/A
EPS Q2Q%350%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Sales Q2Q%6.12%
3.2 Future
The Earnings Per Share is expected to grow by 33.51% on average over the next years. This is a very strong growth
ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y-265.75%
EPS Next 2Y-38.15%
EPS Next 3Y33.51%
EPS Next 5YN/A
Revenue Next Year5.41%
Revenue Next 2Y3.47%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.14, ORGO can be considered very expensive at the moment.
ORGO's Price/Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 94.84% of the companies in the same industry.
When comparing the Price/Earnings ratio of ORGO to the average of the S&P500 Index (27.20), we can say ORGO is valued inline with the index average.
With a Price/Forward Earnings ratio of 209.48, ORGO can be considered very expensive at the moment.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 91.10% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ORGO to the average of the S&P500 Index (23.73), we can say ORGO is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.14 | ||
| Fwd PE | 209.48 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaply inside the industry as 96.62% of the companies are valued more expensively.
ORGO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ORGO is cheaper than 93.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 109.15 | ||
| EV/EBITDA | 13.96 |
4.3 Compensation for Growth
ORGO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 33.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.15%
EPS Next 3Y33.51%
5. Dividend
5.1 Amount
ORGO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORGANOGENESIS HOLDINGS INC
NASDAQ:ORGO (12/23/2024, 12:24:22 PM)
3.205
+0.16 (+5.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.99%
Inst Owner Change2.47%
Ins Owners24.91%
Ins Owner Change-13.71%
Market Cap424.92M
Analysts82
Price Target4.79 (49.45%)
Short Float %11.39%
Short Ratio11.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)3.75%
Max Revenue beat(2)4.78%
Revenue beat(4)3
Avg Revenue beat(4)1.21%
Min Revenue beat(4)-10.41%
Max Revenue beat(4)6.7%
Revenue beat(8)4
Avg Revenue beat(8)0.41%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)8
Avg Revenue beat(16)1.79%
PT rev (1m)0%
PT rev (3m)7.43%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-550.45%
EPS NY rev (1m)61.76%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.64%
Revenue NY rev (1m)2.07%
Revenue NY rev (3m)2.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.14 | ||
| Fwd PE | 209.48 | ||
| P/S | 0.93 | ||
| P/FCF | 109.15 | ||
| P/OCF | 30.6 | ||
| P/B | 1.53 | ||
| P/tB | 1.8 | ||
| EV/EBITDA | 13.96 |
EPS(TTM)0.11
EY3.43%
EPS(NY)0.02
Fwd EY0.48%
FCF(TTM)0.03
FCFY0.92%
OCF(TTM)0.1
OCFY3.27%
SpS3.43
BVpS2.1
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.65% | ||
| ROE | -2.65% | ||
| ROCE | 2.72% | ||
| ROIC | 1.68% | ||
| ROICexc | 2.26% | ||
| ROICexgc | 2.67% | ||
| OM | 2.2% | ||
| PM (TTM) | N/A | ||
| GM | 75.29% | ||
| FCFM | 0.86% |
ROA(3y)8.64%
ROA(5y)2.79%
ROE(3y)15.61%
ROE(5y)-2.42%
ROIC(3y)6.08%
ROIC(5y)N/A
ROICexc(3y)8.72%
ROICexc(5y)N/A
ROICexgc(3y)11%
ROICexgc(5y)N/A
ROCE(3y)9.81%
ROCE(5y)N/A
ROICexcg growth 3Y-44.87%
ROICexcg growth 5YN/A
ROICexc growth 3Y-37.73%
ROICexc growth 5YN/A
OM growth 3Y-28.44%
OM growth 5YN/A
PM growth 3Y-39.22%
PM growth 5YN/A
GM growth 3Y0.55%
GM growth 5Y3.2%
F-Score5
Asset Turnover1.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 16.51 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 59.55% | ||
| Cap/Sales | 2.2% | ||
| Interest Coverage | 1.78 | ||
| Cash Conversion | 51.8% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.09 | ||
| Quick Ratio | 2.74 | ||
| Altman-Z | 2.82 |
F-Score5
WACC10.6%
ROIC/WACC0.16
Cap/Depr(3y)255.15%
Cap/Depr(5y)209.48%
Cap/Sales(3y)6.6%
Cap/Sales(5y)5.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3Y-30.66%
EPS 5YN/A
EPS Q2Q%350%
EPS Next Y-265.75%
EPS Next 2Y-38.15%
EPS Next 3Y33.51%
EPS Next 5YN/A
Revenue 1Y (TTM)1.37%
Revenue growth 3Y8.59%
Revenue growth 5Y17.5%
Sales Q2Q%6.12%
Revenue Next Year5.41%
Revenue Next 2Y3.47%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y-55.42%
EBIT growth 3Y-22.3%
EBIT growth 5YN/A
EBIT Next Year134.74%
EBIT Next 3Y62.84%
EBIT Next 5YN/A
FCF growth 1Y-40.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.33%
OCF growth 3Y78.13%
OCF growth 5YN/A